Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Cell membrane Note=Localizes to the cytoplasm and translocates to the plasma membrane on necroptosis induction. |
Domain |
PF07714 Protein tyrosine kinase |
Function |
Pseudokinase that plays a key role in TNF-induced necroptosis, a programmed cell death process. Activated following phosphorylation by RIPK3, leading to homotrimerization, localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage. Does not have protein kinase activity. |
Biological Process |
GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0070206 protein trimerization GO:0070207 protein homotrimerization GO:0070265 necrotic cell death GO:0070266 necroptotic process GO:0097300 programmed necrotic cell death |
Molecular Function | - |
Cellular Component | - |
KEGG |
hsa04668 TNF signaling pathway |
Reactome |
R-HSA-5357801: Programmed Cell Death R-HSA-5213460: RIPK1-mediated regulated necrosis R-HSA-5218859: Regulated Necrosis |
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MLKL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MLKL in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MLKL in various data sets.
|
Points in the above scatter plot represent the mutation difference of MLKL in various data sets.
|
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MLKL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MLKL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MLKL. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MLKL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MLKL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MLKL |
Name | mixed lineage kinase domain-like |
Aliases | FLJ34389; hMLKL; Mixed lineage kinase domain-like protein |
Chromosomal Location | 16q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MLKL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |